Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trialW. Timothy Garvey, Anuj Bhargava, Naveed Sattar et al.|The Lancet|2023Cited by 676
Tirzepatide for Obesity Treatment and Diabetes PreventionAnia M. Jastreboff, Irina Jouravskaya, Carel W. le Roux et al.|New England Journal of Medicine|2024Cited by 368